There is considerable evidence that injection of botulinum toxin (BTX) into muscles with spastic overactivity reduces resistance to passive movement in joints supplied by the injected muscles. The demonstration of improvement in active performance of the paretic limbs has been only anecdotal to date
Nerve stimulation boosts botulinum toxin action in spasticity
✍ Scribed by Emma Frasson; Alberto Priori; Barbara Ruzzante; Giuseppe Didonè; Laura Bertolasi
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 137 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Spasticity leads to functional and structural changes in nerves and muscles, which alter skeletal muscle function. To evaluate whether short‐term electrical nerve stimulation (NS) improves the effect of botulinum toxin in spastic skeletal muscle, we studied changes in the amplitude of the compound muscle action potential (CMAP) recorded from the extensor digitorum brevis (EDB) muscle in response to peroneal nerve stimulation at the ankle after injection of botulinum toxin type A (BTXA) alone or combined with short‐term NS. In paraparetic patients, both EDB muscles were injected with BTXA; and NS was applied to one EDB muscle alone. All patients received a 30‐minute session of electrical NS once a day for 5 consecutive days after BTXA injection. We used two different stimulation frequencies (low‐frequency, 4 Hz; and high‐frequency, 25 Hz). EDB‐CMAP amplitudes were evaluated before BTXA injection (day 0) and changes in CMAP amplitude, expressed as a percentage (CMAP%), were measured at various time points over a 30‐day period after BTXA injection. We compared changes in the CMAP% amplitude on the stimulated and contralateral nonstimulated sides. We also studied the electromyographic activity recorded from EDB muscles over a 30‐day period. CMAP% amplitudes measured at all time points after BTXA injections were significantly reduced in both EDB muscles. On days 4, 10, and 15, the CMAP% amplitude reduction was significantly greater for the low‐frequency stimulated EDB than for the contralateral nonstimulated EDB. No significant differences in CMAP% were observed for the high‐frequency stimulated and nonstimulated EDB. After BTXA injection, spontaneous activity appeared in both EDB muscles; but it appeared earlier and involved larger areas in the stimulated than in the nonstimulated EDB. In conclusion, short‐term NS accelerates the effectiveness of intramuscular BTXA injections on the neuromuscular blockade in patients with spastic paraparesis and could induce a rapid and persistent improvement in spasticity. Its action probably arises mainly from low‐frequency NS. © 2005 Movement Disorder Society
📜 SIMILAR VOLUMES
Celiac disease (CD), which is one of the most important malabsorptive diseases in adults, has been associated with several neurological disorders including peripheral neuropathy, cerebellar ataxia, myopathy, and attention deficit hyperactivity disorders. Recently, 2 independent studies 1,2 reported
Local injection of botulinum toxin (BT) is a wellestablished treatment option for spastic movement disorders in children. BT blocks the release of acetylcholine from the axon terminal into the synaptic cleft of the motor endplate resulting in paresis of the injected musculature. Such localised, temp
Physical and occupational therapists play important roles in the evaluation and management of patients receiving botulinum toxin injections for spasticity. Baseline evaluation includes areas beyond the muscles being injected, since local spasticity reduction may lead to more widespread functional ch